Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Raoul TibesHeidi E KosiorekAmylou C DueckJeanne M PalmerLisa SproatJames BogenbergerShahrukh K. HashmiRuben A MesaWilliam HoganMark R LitzowAref A Al-KaliPublished in: Cancer (2023)
Our study shows that AZA + SON are a safe combination in a patient with MN. Similar to other hedgehog inhibitors, this combination yielded limited response rate in patients with myeloid neoplasms.